학술논문
Assessment of chimerism and immunomodulation to prevent post-transplantation relapse in childhood acute myeloblastic leukemia: is it the right approach?
Document Type
Report
Author
Cousin, Elie; Oger, Emmanuel; Dalle, Jean-Hugues; Bertrand, Yves; Pertuisel, Sophie; Pochon, Cecile; Galambrun, Claire; Simon, Pauline; Bruno, Benedicte; Paillard, Catherine; Schneider, Pascale; Rohrlich, Pierre; de La Tour, Régis Peffault; Freycon, Claire; Eliaou, Jean-Francois; Semana, Gilbert; Jonveaux, Philippe; Drunat, Severine; Bordigoni, Pierre; Gandemer, Virginie
Source
Subject
*ACUTE myeloid leukemia
*CHIMERISM
*IMMUNOREGULATION
*
*
Language
ISSN
0888-0018
Abstract
Relapse of acute myeloblastic leukemia (AML) after first allogenic hematopoietic stem-cell transplantation (allo-HSCT) is a fatal complication. Sixty-five children transplanted for AML were included in a prospective national study from June 2005 to July 2008 to explore the feasibility of preemptive immune modulation based on the monitoring of blood chimerism. Relapse occurred in 23 patients (35%). The median time between the last complete chimerism and relapse was 13.5 days (2-138). Prompt discontinuation of cyclosporin and the administration of donor lymphocyte infusions (DLIs) based on chimerism monitoring failed as a preemptive tool, either for detecting relapse or certifying long-term remission. [ABSTRACT FROM AUTHOR]